Clinician-reported data from 21 countries all over the world were aggregated into a dataset of 1,540 patients. Of these, 476 (30.9%) with suspected and 776 (50.4%) with confirmed COVID-19 were included in the analysis.
Older age, progressive MS, and higher EDSS were associated with a higher likelihood of hospital admission but being female with a lower likelihood. Progressive MS and higher disability were associated with a higher risk of intensive care unit admission. Mortality risk was elevated in patients with progressive MS, older age, and higher disability.
The adjusted prevalence ratios (aPRs) of hospitalisation (313 events) were established per DMT, with dimethyl fumarate as comparison. Use of anti-CD20 DMT ocrelizumab and rituximab was positively associated with hospital admission (aPRs 1.19 and 1.58), intensive care admission (aPRs 3.53 and 4.12), and the need for artificial ventilation (aPRs 3.17 and 7.27). There was no association between any DMT and death. Risk of all 3 clinical outcomes was higher in anti-CD20 users (n=343) compared with all other DMT users (n=492): hospitalisation aPR 1.49; intensive care admission aPR 2.55; and ventilation aPR 3.05. These risks were also higher compared with natalizumab: hospitalisation aPR 1.99; intensive care admission aPR 2.39; ventilation aPR 2.84. Associations persisted when restricting analysis to confirmed COVID-19 cases only.
There are different possible explanations for the consistently stronger association with COVID-19 severity of rituximab versus ocrelizumab. The most simple and appropriate explanation is the difference in affinities, with rituximab binding the exact same epitope on CD20 but binding more strongly.
An update from Roche's pharmacovigilance program did not confirm the above findings for ocrelizumab. Notwithstanding the limitations of the data sources, the experience of ocrelizumab-treated MS patients with COVID-19 appeared in line with the data reported from the general population and MS datasets [2]. The majority of SARS-CoV-2 infections in MS patients treated with ocrelizumab across Roche clinical trials (n=51; 26 confirmed) and post-marketing spontaneous reports (n=307; 263 confirmed) with reported severity, resulted in mild-to-moderate disease. Case fatality rates in ocrelizumab-treated MS patients were in line with the general population and MS datasets overall. Ocrelizumab-treated patients with risk factors associated with worse COVID-19 outcomes appeared to experience more severe disease, which is also in line with published experience.
- Simpson-Yap S, et al. First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes. MSVirtual 2020, Abstract SS02.04.
- Hughes R, et al. COVID-19 in persons with multiple sclerosis treated with ocrelizumab: pharmacovigilance update. MSVirtual 2020, Abstract SS02.05.
Posted on
Previous Article
« Black MS patients have poorer COVID-19 outcomes Next Article
Age and EDSS are risk factors for severe COVID-19 »
« Black MS patients have poorer COVID-19 outcomes Next Article
Age and EDSS are risk factors for severe COVID-19 »
Table of Contents: MS Virtual 2020
Featured articles
Online First
Positive results for vagus nerve stimulation in RA
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Positive results for vagus nerve stimulation in RA
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
September 10, 2020
Alemtuzumab efficacy and safety data of over 9 years
November 25, 2020
Update on estimated PML risk related to fingolimod
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com